# Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC

> **NCT04989322** · PHASE2 · UNKNOWN · sponsor: **Dr Joanne CHIU** · enrollment: 46 (estimated)

## Conditions studied

- Nsclc
- EGFR Activating Mutation
- EGF-R Positive Non-Small Cell Lung Cancer
- ALK Gene Rearrangement Positive
- ROS1 Gene Rearrangement
- ROS1 Positive NSCLC - Reactive Oxygen Species 1 Positive Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Lenvatinib
- **DRUG:** Pemetrexed
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT04989322
- **Lead sponsor:** Dr Joanne CHIU
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-05
- **Primary completion:** 2024-08
- **Final completion:** 2024-12
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2021-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04989322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04989322, "Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04989322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*